Why the study?
Do anti-beta1-adrenergic receptor autoantibodies from cardiomyopathy patients reduce beta1-adrenergic receptor expression in neonatal rat cardiomyocytes?
Population
Cultured neonatal rat cardiomyocytes
Comparison
Incubation with anti-beta1-adrenergic receptor… vs Incubation with the beta-adrenergic agonist…
Design
Preclinical
Follow-up
72 hours
Authors
Loading...
Suggests autoantibodies may drive β1-AR downregulation in cardiomyopathy; leaves open clinical relevance and bisoprolol effects in patients.
Do anti-beta1-adrenergic receptor autoantibodies from cardiomyopathy patients reduce beta1-adrenergic receptor expression in neonatal rat cardiomyocytes?
Anti-beta1-adrenergic receptor autoantibodies from dilated cardiomyopathy patients downregulate beta1-adrenergic receptor expression in cardiomyocytes, mimicking the receptor profile seen in failing hearts.
Podlowski et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: